Milestone enrolls trial patient: USD 6.40 target for Milestone Pharmaceuticals stock

Published on 10/05/2026 at 20:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ReVeRA-301 targets 150 treated events with a 70 mg regimen. Seven brokerages rate Milestone Pharmaceuticals stock Moderate Buy.

MIST, CA59935V1076, Illustration mit AI erstellt.

Milestone Pharmaceuticals (CA59935V1076) enrolled the first Canadian participant in its ReVeRA-301 Phase 3 trial on September 24, 2026, while the average 12-month analyst target stands at USD 6.40. StockTitan reported the Canadian enrollment, and MarketBeat cited the consensus target on September 21, 2026.

Canadian enrollment expands the trial

ReVeRA-301 is evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate, or AFib-RVR. The study uses a 70 mg repeat-dose regimen and targets 150 treated events in a randomized, double-blind, placebo-controlled Phase 3 design, according to StockTitan.

The primary endpoint measures a reduction in ventricular rate within 30 minutes, while a secondary endpoint tracks patient-reported symptom improvement. Milestone is pursuing a single-study supplemental new drug application pathway for AFib-RVR, but the indication remains under clinical evaluation rather than FDA approval.

Revenue trails the Q2 consensus

The commercial test is equally important. In fiscal Q2 2026, revenue reached USD 0.56 million versus USD 0.82 million consensus, while diluted earnings per share was minus USD 0.21 versus minus USD 0.20 consensus, MarketBeat reported.

That comparison puts the trial update in context: Milestone is advancing a larger indication while its approved PSVT product, CARDAMYST, is still building commercial scale. The next valuation debate therefore turns on whether clinical expansion can translate into revenue growth faster than operating losses consume capital.

Market value remains below USD 100 million

Milestone Pharmaceuticals had a market capitalization of USD 97.9 million as of October 5, 2026. Its 52-week range was USD 0.75 to USD 3.06, and MIST was trading at USD 0.79 on Nasdaq at 2:35 p.m. ET on October 5, 2026.